CAR T-cell therapy uses the target specificity of antibody therapy to direct the cytotoxic immune response4

The autologous anti-CD19 CAR T-cell therapy, TECARTUS, is individually prepared from each patient’s T cells in a 6-step process1:



Obtain peripheral blood mononuclear cells

T cells


Isolate T cells to reduce the likelihood that circulating tumor cells drive the exhaustion of CAR T cells

anti-CD3 and anti-CD28 antibodies + IL-2


Activate T cells using anti-CD3 and anti-CD28 antibodies + IL-2

anti-CD19 CAR transgene


Insert anti-CD19 CAR transgene

CAR T cell expansion

T-cell Expansion

In cell culture, expand the number of CAR T cells to achieve dose

CAR T cells in suspension for infusion


Formulate CAR T cells into suspension for infusion

*24-month follow-up analysis was conducted after all 68 patients treated with TECARTUS in the ZUMA-2 study had the opportunity to be followed for at least 24 months or until death or withdrawal from the study.5 24-month analysis is not included in the USPI.

CAR=chimeric antigen receptor; CD=cluster of differentiation; IL=interleukin; R/R=relapsed or refractory; USPI=US Prescribing Information.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. U.S. FDA approves Kite’s TECARTUS®, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma. News release. Kite, a Gilead Company; July 24, 2020. Accessed February 13, 2023.’s-Tecartus™-the-First-and-Only-CAR-T-Treatment-for-Relapsed-or-Refractory-Mantle-Cell-Lymphoma 3. Data on file [1]. Kite Pharma, Inc; 2022. 4. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(suppl 1):S3-S9. 5. Data on file [2]. Kite Pharma, Inc; 2022.